Sol-Gel Technologies Ltd. (SLGL)
| Market Cap | 222.08M +99.5% |
| Revenue (ttm) | 1.80M -92.5% |
| Net Income | -16.34M |
| EPS | -5.59 |
| Shares Out | 3.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,234 |
| Open | 70.00 |
| Previous Close | 69.50 |
| Day's Range | 67.51 - 70.00 |
| 52-Week Range | 28.81 - 97.97 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 152.50 (+124.83%) |
| Est. Earnings | Nov 19, 2026 |
About SLGL
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-... [Read more]
Financial Performance
In 2025, Sol-Gel Technologies's revenue was $19.39 million, an increase of 68.04% compared to the previous year's $11.54 million. Losses were -$6.13 million, -42.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price target is $152.5, which is an increase of 124.83% from the latest price.
News
Sol-Gel Technologies Transcript: KOL event
Management presented SGT-610 as a potential chronic topical option to reduce Gorlin-related BCCs and surgery burden, with phase III top-line results projected next month. KOLs described 30% fewer new tumors as meaningful; commercial forecasts assume 4,000 peak U.S. patients and $860 million in sales.
Sol-Gel Technologies initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Imogen Mansfield initiated coverage of Sol-Gel Technologies (SLGL) with an Overweight rating. Sol-Gel is advancing SGT-610, a topical Hedgehog inhibitor designed to prevent n...
Sol-Gel Technologies initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Sol-Gel Technologies (SLGL) with an Overweight rating.
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today ...
Sol-Gel Technologies announces last patient visit in SGT-610 trial
Sol-Gel Technologies (SLGL) announced that the last patient has completed the last scheduled study visit in the company’s pivotal Phase 3 clinical trial evaluating SGT-610 for the prevention of BCC…
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome Top-line results remain on track for late November 20...
Sol-Gel Technologies Earnings release: Q2 2026
Sol-Gel Technologies released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today a...
Sol-Gel Technologies initiated with an Outperform at Mizuho
Mizuho initiated coverage of Sol-Gel Technologies (SLGL) with an Outperform rating and $285 price target The firm sees the company’s SGT-610 as a potential first-in-class FDA-approved therapy to preve...
Sol-Gel Technologies initiated with a Buy at TD Cowen
TD Cowen analyst Stacy Ku initiated coverage of Sol-Gel Technologies (SLGL) with a Buy rating and no price target The company’s SGT-610 is in an “optimized” Phase III trial for…
Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year
Reports Q1 revenue $108,000 vs. $1.03M last year. Mori Arkin, executive chairman of Sol-Gel, stated: “The first quarter of 2026 was a period of substantial progress on every front that…
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten...
Sol-Gel Technologies Earnings release: Q1 2026
Sol-Gel Technologies released its Q1 2026 earnings on May 28, 2026, summarizing the period's financial results.
Sol-Gel Technologies 459K share Spot Secondary priced at $72.00
TD Cowen and LifeSci Capital are acting as joint book running managers for the offering.
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the ...
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31...
Sol-Gel Technologies Annual report: Q4 2025
Sol-Gel Technologies has published its Q4 2025 annual report on March 19, 2026.
Sol-Gel Technologies Slides: Corporate presentation
Sol-Gel Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
Sol-Gel Technologies price target raised to $110 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Sol-Gel Technologies (SLGL) to $110 from $50 and keeps a Buy rating on the shares. The firm now anticipates that SGT-610 may…
Sol-Gel decides not to advance SGT-210 development in Darier disease
Sol-Gel Technologies (SLGL) provided an update following the unblinding of clinical data from its vehicle-controlled proof-of-concept Phase 1b study of SGT-210 on Darier disease. Following unblinding,...
Sol-Gel Technologies Earnings release: Q3 2025
Sol-Gel Technologies released its Q3 2025 earnings on November 20, 2025, summarizing the period's financial results.
Sol-Gel Technologies reports Q3 EPS ($2.13) vs (13c) last year
Reports Q3 revenue $400k vs $5.4M last year. Mori Arkin, Executive Chairman of Sol-Gel, stated: “Sol-Gel continued to make steady progress in the third quarter as we advance our late-stage…
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potential In September 202...
Sol-Gel Technologies target adjusted to $50 from $6 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Sol-Gel Technologies (SLGL) to $50 from $6 and keeps a Buy rating on the shares to reflect the 1-for-10…
Sol-Gel Technologies announces Health Canada approval of EPSOLAY
Sol-Gel Technologies (SLGL) announced that on August 27, 2025 Health Canada issued a Notice of Compliance, NOC, for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults. This…